{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-297211","form_type":"8-K","ticker":"VERA","cik":"0001831828","company_name":"Vera Therapeutics, Inc.","filed_at":"2026-07-07T16:45:57+00:00","discovered_at":"2026-07-07T16:47:00.266190+00:00","generated_at":"2026-07-07T16:47:09.155090+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"medium","headline":"FDA grants accelerated approval for Vera's TRUTAKNA (atacicept) in IgA nephropathy","bullets":["FDA granted accelerated approval for TRUTAKNA (atacicept-vymj) to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.","Approval announced on July 7, 2026; this is a significant regulatory milestone for Vera Therapeutics.","The accelerated approval is based on reduction of proteinuria as a surrogate endpoint."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-297211","json":"https://secwatch.observer/filing/0001193125-26-297211.json","markdown":"https://secwatch.observer/filing/0001193125-26-297211.md","text":"https://secwatch.observer/filing/0001193125-26-297211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526297211/0001193125-26-297211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831828/000119312526297211/vera-20260707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-07T16:47:09.155090+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}